Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
October 14, 2024 12:33 ET
|
Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
June 24, 2024 09:27 ET
|
Spherix Global Insights
EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
April 16, 2024 07:14 ET
|
Arch Biopartners
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a...
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca
December 19, 2023 10:00 ET
|
Related Sciences
Former CEOs and executives from Genentech, Novartis, Seagen, Pfizer, and Celgene join drug AI/ML drug discovery firm Related Sciences as senior advisors.
BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie in neuer Krebsindikation
October 19, 2023 06:45 ET
|
BioNTech SE
Grundlage für Phase-2-Studienstart waren Daten einer klinischen Phase-1-Studie zur Untersuchung der Sicherheit und Verträglichkeit von Autogene Cevumeran (BNT122, RO7198457) in Kombination mit...
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
October 19, 2023 06:45 ET
|
BioNTech SE
Initiation of Phase 2 builds on data from a Phase 1 clinical trial evaluating the safety and tolerability of autogene cevumeran (BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Cancer Support Community Honors Genentech with Founders Award for Innovation
November 01, 2021 16:11 ET
|
Cancer Support Community
WASHINGTON, D.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) has announced groundbreaking biotechnology company Genentech, a member of The Roche Group, as the recipient of...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
October 05, 2020 10:13 ET
|
ImmunoPhotonics, Inc.
ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...